Intestinal Lymph Flow, and Lipid and Drug Transport Scale Allometrically From Pre-clinical Species to Humans

The intestinal lymphatic system transports fluid, immune cells, dietary lipids, and highly lipophilic drugs from the intestine to the systemic circulation. These transport functions are important to health and when dysregulated contribute to pathology. This has generated significant interest in approaches to deliver drugs to the lymphatics. Most of the current understanding of intestinal lymph flow, and lymphatic lipid and drug transport rates, comes from in vitro studies and in vivo animal studies. In contrast, intestinal lymphatic transport studies in human subjects have been limited. Recently, three surgical patients had cannulation of the thoracic lymph duct for collection of lymph before and during a stepwise increase in enteral feed rate. We compared these data to studies where we previously enterally administered controlled quantities of lipid and the lipophilic drug halofantrine to mice, rats and dogs and collected lymph and blood (plasma). The collected lymph was analyzed to compare lymph flow rate, triglyceride (TG) and drug transport rates, and plasma was analyzed for drug concentrations, as a function of enteral lipid dose across species. Lymph flow rate, TG and drug transport increased with lipid administration in all species tested, and scaled allometrically according to the equation A = aME where A is the lymph transport parameter, M is animal body mass, a is constant and E is the allometric exponent. For lymph flow rate and TG transport, the allometric exponents were 0.84–0.94 and 0.80–0.96, respectively. Accordingly, weight normalized lymph flow and TG mass transport were generally lower in larger compared to smaller species. In comparison, mass transport of drug via lymph increased in a greater than proportional manner with species body mass with an exponent of ∼1.3. The supra-proportional increase in lymphatic drug transport with species body mass appeared to be due to increased partitioning of drug into lymph rather than blood following absorption. Overall, this study proposes that intestinal lymphatic flow, and lymphatic lipid and drug transport in humans is most similar to species with higher body mass such as dogs and underestimated by studies in rodents. Notably, lymph flow and lipid transport in humans can be predicted from animal data via allometric scaling suggesting the potential for similar relationships with drug transport.

[1]  A. Eichmann,et al.  The Intestinal Lymphatic System: Functions and Metabolic Implications , 2018, Cellular and molecular gastroenterology and hepatology.

[2]  A. Johnston,et al.  Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size‐dependent and primarily occurs within the liver and mesentery , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[3]  G. Koh,et al.  Organ-specific lymphatic vasculature: From development to pathophysiology , 2018, The Journal of experimental medicine.

[4]  T. Petrova,et al.  Intestinal lymphatic vasculature: structure, mechanisms and functions , 2017, Nature Reviews Gastroenterology &Hepatology.

[5]  M. Swartz,et al.  Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges , 2017, Advanced drug delivery reviews.

[6]  C. Porter,et al.  Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability. , 2016, Angewandte Chemie.

[7]  G. Edwards,et al.  Lymphatic Transport and Lymphocyte Targeting of a Triglyceride Mimetic Prodrug Is Enhanced in a Large Animal Model: Studies in Greyhound Dogs. , 2016, Molecular pharmaceutics.

[8]  J. Windsor,et al.  Indications, techniques, and clinical outcomes of thoracic duct interventions in patients: a forgotten literature? , 2016, The Journal of surgical research.

[9]  B. Cosimelli,et al.  Understanding Oxadiazolothiazinone Biological Properties: Negative Inotropic Activity versus Cytochrome P450-Mediated Metabolism. , 2016, Journal of medicinal chemistry.

[10]  D. I. Givens,et al.  Fatty Acid Composition , 2016 .

[11]  Christopher J. H. Porter,et al.  From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity , 2015, Nature Reviews Drug Discovery.

[12]  O. Dirsch,et al.  Monitoring of systemic and hepatic hemodynamic parameters in mice. , 2014, Journal of visualized experiments : JoVE.

[13]  V. Stella,et al.  Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[14]  P. Tso,et al.  A Mouse Model to Evaluate the Impact of Species, Sex, and Lipid Load on Lymphatic Drug Transport , 2013, Pharmaceutical Research.

[15]  R. Yolken,et al.  Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis , 2012, Proceedings of the National Academy of Sciences.

[16]  Timothy Kassis,et al.  Dual-channel in-situ optical imaging system for quantifying lipid uptake and lymphatic pump function. , 2012, Journal of biomedical optics.

[17]  K. Alitalo,et al.  The lymphatic vasculature in disease , 2011, Nature Medicine.

[18]  J. Brandon Dixon,et al.  Lymphatic lipid transport: sewer or subway? , 2010, Trends in Endocrinology & Metabolism.

[19]  Christopher J. H. Porter,et al.  The Mechanism of Lymphatic Access of Two Cholesteryl Ester Transfer Protein Inhibitors (CP524,515 and CP532,623) and Evaluation of Their Impact on Lymph Lipoprotein Profiles , 2010, Pharmaceutical Research.

[20]  G. Edwards,et al.  The Role of the Intestinal Lymphatics in the Absorption of Two Highly Lipophilic Cholesterol Ester Transfer Protein Inhibitors (CP524,515 and CP532,623) , 2010, Pharmaceutical Research.

[21]  Christopher J H Porter,et al.  Lymphatic Transport of Methylnortestosterone Undecanoate (MU) and the Bioavailability of Methylnortestosterone Are Highly Sensitive to the Mass of Coadministered Lipid after Oral Administration of MU , 2009, Journal of Pharmacology and Experimental Therapeutics.

[22]  F. W. Wiegel,et al.  Scaling aspects of lymphocyte trafficking. , 2009, Journal of theoretical biology.

[23]  Anatoliy A Gashev,et al.  Lymphatic Vessels: Pressure‐ and Flow‐dependent Regulatory Reactions , 2008, Annals of the New York Academy of Sciences.

[24]  C. Porter,et al.  Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs , 2007, Nature Reviews Drug Discovery.

[25]  C. Porter,et al.  The Lymph Lipid Precursor Pool Is a Key Determinant of Intestinal Lymphatic Drug Transport , 2006, Journal of Pharmacology and Experimental Therapeutics.

[26]  F. W. Wiegel,et al.  The complexity of the Immune System: Scaling Laws , 2006 .

[27]  K. Voigt,et al.  Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man , 1976, Klinische Wochenschrift.

[28]  Christopher J. H. Porter,et al.  Intestinal Lymphatic Transport of Halofantrine Occurs After Oral Administration of a Unit-Dose Lipid-Based Formulation to Fasted Dogs , 2003, Pharmaceutical Research.

[29]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[30]  David M. Shackleford,et al.  Contribution of Lymphatically Transported Testosterone Undecanoate to the Systemic Exposure of Testosterone after Oral Administration of Two Andriol Formulations in Conscious Lymph Duct-Cannulated Dogs , 2003, Journal of Pharmacology and Experimental Therapeutics.

[31]  S. Lindstedt,et al.  Use of allometry in predicting anatomical and physiological parameters of mammals , 2002, Laboratory animals.

[32]  G. Edwards,et al.  A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. , 2001, Journal of pharmaceutical sciences.

[33]  C. Porter,et al.  Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. , 2000, Journal of pharmaceutical sciences.

[34]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[35]  C. Mansbach,et al.  Intracellular movement of triacylglycerols in the intestine. , 1998, Journal of lipid research.

[36]  C. Porter,et al.  Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. , 1996, Journal of pharmaceutical sciences.

[37]  C. Porter,et al.  Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. , 1996, Journal of pharmaceutical sciences.

[38]  P. Conzen,et al.  The effects of sevoflurane, halothane, enflurane, and isoflurane on hepatic blood flow and oxygenation in chronically instrumented greyhound dogs. , 1992, Anesthesiology.

[39]  I I Mansbach CM,et al.  Portal transport of absorbed lipids in rats. , 1991, The American journal of physiology.

[40]  M. Suzuki,et al.  Increased lymphocyte transport by lipid absorption in rat mesenteric lymphatics. , 1987, The American journal of physiology.

[41]  V. Stella,et al.  Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules , 1986 .

[42]  D. Capuzzi,et al.  Intestinal triglycerides are derived from both endogenous and exogenous sources. , 1985, The American journal of physiology.

[43]  G. McDonald,et al.  Portal venous transport of long-chain fatty acids absorbed from rat intestine. , 1980, The American journal of physiology.

[44]  P. Wood,et al.  Composition of human chyle chylomicrons following single fat feedings. , 1969, The American journal of clinical nutrition.

[45]  R. Blomstrand,et al.  The fatty acid composition of human thoracic duct lymph lipids. , 1960, The Journal of clinical investigation.

[46]  I. Chaikoff,et al.  Intestinal lymph as pathway for transport of absorbed fatty acids of different chain lengths. , 1951, The American journal of physiology.